Abstract
The outcome for 758 consecutive patients who had received one or more chemotherapy regimens for recurrent or metastatic breast cancer is presented. The response rate following first line treatment was 34%. Median duration of response was 7.8 months, median time to progression was 3.7 months and median survival was 7.9 months. The only factor predicting for response, of factors recorded at presentation and at initiation of chemotherapy, was the use of anthracycline based regimens, though this may reflect the patient selection policy. Initial disease free interval, presence of liver metastases and use of anthracyclines were significantly related to time to progression. Several factors related to survival following first chemotherapy, but anthracycline usage showed only a very weak correlation. One third of patients (249/758) received two or more chemotherapy regimens. The response rate (16%) and median time to progression (2.3 months) were significantly worse than for first line treatment. The outcome after third line chemotherapy was very similar to that observed following second line treatment. Achievement of an objective response with first line chemotherapy predicted for second response, but with insufficient power to be of use in selecting patients for subsequent chemotherapy. Time to progression following first line chemotherapy did not influence that after second line treatment.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gregory, W., Smith, P., Richards, M. et al. Chemotherapy of advanced breast cancer: outcome and prognostic factors. Br J Cancer 68, 988–995 (1993). https://doi.org/10.1038/bjc.1993.467
Issue Date:
DOI: https://doi.org/10.1038/bjc.1993.467
This article is cited by
-
CT-Guided Radiofrequency Ablation in Patients with Hepatic Metastases from Breast Cancer
CardioVascular and Interventional Radiology (2009)
-
Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer
Cancer Chemotherapy and Pharmacology (2008)
-
Therapieresponse von Lebertumoren nach selektiver interner Radiotherapie
Der Radiologe (2008)